Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 23, 2026 (Updated: June 10, 2026)

The BioPharm Brief: Fibrosis, Bispecific ADCs, and Billion-Dollar Deals

This episode explores a first-in-class antibody entering the clinic for kidney fibrosis, the world's first approved bispecific ADC, and a major acquisition that strengthens AbbVie's immunology pipeline.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s stories highlight three trends influencing the industry right now: the continued expansion of biologics into difficult-to-treat diseases, growing momentum for next-generation antibody-drug conjugates, and ongoing investment in immunology assets with late-stage potential.

First, Mediar Therapeutics has advanced MTX-439 into a Phase I clinical trial for chronic kidney disease-associated fibrosis. The investigational therapy is a first-in-class anti-SMOC2 monoclonal antibody designed to target fibrosis, a key driver of disease progression in chronic kidney disease. Fibrosis remains a major unmet medical need across multiple indications, and MTX-439 represents an effort to intervene upstream in the biological mechanisms that contribute to tissue scarring. The phase I study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.

In oncology, China's National Medical Products Administration has approved Iza-Bren for recurrent or metastatic nasopharyngeal carcinoma. The approval marks a notable milestone as the first globally approved bispecific antibody-drug conjugate. The therapy combines dual-targeting capabilities with an ADC mechanism, reflecting broader industry efforts to improve tumor selectivity while maintaining potent anti-cancer activity. The approval could provide insight into how future bispecific ADCs are developed and evaluated worldwide.

Finally, AbbVie has agreed to acquire Apogee Therapeutics for approximately $10.9 billion. The deal centers on zumilokibart, an investigational IL-13 antibody being developed for inflammatory diseases. The acquisition strengthens AbbVie's immunology portfolio as competition intensifies across immune-mediated conditions. It also underscores continued interest in cytokine-targeting biologics as companies seek differentiated approaches beyond established therapies.

Those are today's top stories shaping biopharma.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • Mediar's MTX-439 enters the clinic as a first-in-class anti-SMOC2 antibody targeting fibrosis in chronic kidney disease.
  • Iza-bren becomes the first bispecific ADC to receive global regulatory approval, highlighting continued innovation in targeted oncology.
  • AbbVie's $10.9 billion acquisition of Apogee Therapeutics reinforces the industry's focus on next-generation immunology biologics and IL-13-targeted therapies.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more